Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

  • STATUS
    Recruiting
  • End date
    Dec 3, 2024
  • participants needed
    170
  • sponsor
    St. Olavs Hospital
Updated on 3 December 2021
botulinum toxin
beta blockers
headache
antidepressants
botulinum toxin type a
botox
chronic migraine
episodic migraine
severe headache

Summary

This is a clinical trial to assess the efficacy of botox treatment of the sphenopalatine ganglion as an add-on treatment in drug resistant migraine. An injection targeting the ganglion is made possible by an image-guided device developed specifically for this purpose (MultiGuide) Study participants will be randomized to either placebo or botox after a 4 week run-in period. First, one injection will be given towards both the right and the left ganglion. After that there will be a follow-up of 12 weeks for efficacy and safety evaluation. The main efficacy measure is change in number of moderate to severe headache days before and after injection.

Details
Condition Migraine, Primary Stabbing Headache, Migraine (Adult), Migraine and Cluster Headaches, Migraine (Pediatric), migraines
Treatment Placebo, Botulinum Toxin Type A
Clinical Study IdentifierNCT04069897
SponsorSt. Olavs Hospital
Last Modified on3 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

The participants must meet all of the inclusion criteria to participate in
this study
Informed and written consent
Male or female, between 18 and 70 years of age
Masters a Scandinavian language at level sufficient to fully understand the written and verbal study information
Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria 1.3. for chronic migraine at time of inclusion
Chronic migraine at least for a period of 1 year prior to inclusion
Debut of episodic migraine before the age of 50, and chronic migraine before the age of 65
The condition is pharmacologically refractory as defined in this study as insufficient treatment effect, contraindication(s) or intolerable side effect(s) of at least 3 medications from at least 2 of the following medication (drug) classes
Beta-blockers
RA(A)S-inhibitors
Calcium-antagonists
Antiepileptic drugs
Tricyclic antidepressants
Botulinum toxin A
CGRP antagonists
Subject has had no change in type, dosage or dose frequency of preventive headache medications < 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer
Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during the whole study period
In the case of women of childbearing potential (WOCBP) they have to commit to highly effective contraception in a period of 4 weeks after injection (for details, confer section 4.3)
Ability to understand study procedures and to comply with them for the entire length of the study

Exclusion Criteria

All candidates meeting any of the exclusion criteria at baseline or visit 2
will be excluded from study participation
Allergy or hypersensitivity reactions to marcaine, lidocaine, xylocaine, adrenaline, any botulinum toxin or similar substances
Subject is unable to differentiate migraine from other concomitant headaches
Subject with secondary headache conditions, with the exception of medication overuse headache
Non-responder in regular clinical practice to preventive medications from 6 of the following 7 drug classes
Beta-blockers
RA(A)S-inhibitors
Calcium-antagonists
Antiepileptic drugs
Tricyclic antidepressants
Botulinum toxin A
CGRP antagonists
Subject has had a change in type, dosage or dose frequency of preventive headache medications < 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer
Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period, eg. prior to IMP administration
Botulinum toxin injections in the head and neck region, as part of migraine treatment or otherwise indicated on medical or cosmetic grounds, in the last 4 months before inclusion
The discontinuation of CGRP-antagonists within 3 months before study inclusion or 5 half-lives, whichever is longer
Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study inclusion or 5 half-lives, whichever is longer
Subject is currently participating or has participated in the last 3 months in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device
Subject has had previous radiofrequency ablation, balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the trigeminal ganglion or any branch of the trigeminal nerve
Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the SPG
Subject has had blocks of short-acting anaesthetics of the SPG in the last 3 months
Subject is or has been treated with occipital nerve stimulation or deep brain stimulation
Ongoing abuse of drugs (including narcotics) or alcohol
More than 4 days of opioid use per month (including codeine and tramadol), and any use of barbiturates
Treatment with pharmacological substances prior to SPG-injection that may interact with BTA (aminoglycosides, spectinomycin, neuromuscular blockers, both depolarizing agents (such as succinylcholine) or non-depolarizing (tubocurarine derivates), and anticholinesterases)
Inadequate contraceptive use. Women of childbearing potential (WOCBP) who do not use highly effective contraception (HEC) or use other medication that may interact and/or otherwise reduce the efficacy of the contraceptive agents in use
Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary at the planned injection site that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure
Facial anomaly or trauma which renders the procedure difficult
Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms
Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months
Patients with comorbid psychiatric disorders with psychotic or other symptoms making compliance with the study protocol difficult, at the discretion of the investigator
Patients exhibiting a high degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator
Patients with disorders that severely inhibits lacrimation, at the discretion of the investigator
Patients with previous ischemic cardiovascular and cerebrovascular disorder with, in the opinion of the investigator, a moderate to high risk of new ischemic episodes
Known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection
Subject has a history of bleeding disorders or coagulopathy, that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure
Unable to stop antithrombotic medication e.g. platelet aggregation inhibitors and/or anticoagulation therapy, prior to procedure
The patient cannot participate or successfully complete the study, in the opinion of their healthcare provider or the investigator, for any of the following reasons
mentally or legally incapacitated or unable to give consent for any reason
in custody due to an administrative or a legal decision, under tutelage, or being admitted to a sanatorium or social institution
has any other condition, which, in the opinion of the investigator, makes the patient inappropriate for inclusion in the study
The patient is a study centre employee who is directly involved in the study or the relative of such an employee
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note